Papillomavirus-associated squamous skin cancers following transplant immunosuppression: One Notch closer to control

Cancer Treatment Reviews

Volumn 40, Issue 2, 2014, Pages 205-214

  Connolly, Kate ^a   Manders, Pete ^a   Earls, Peter ^a   Epstein, Richard J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Carcinogenesis; Immunosuppression; Papillomavirus; Skin cancer; Vaccines

Indexed keywords

ANTILEUKEMIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; INTERLEUKIN 10; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOTCH RECEPTOR; PREDNISOLONE; PROTEIN E6; PROTEIN E7; PROTEIN P53; RAF PROTEIN; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; TACROLIMUS; VEMURAFENIB; VISMODEGIB; WART VIRUS VACCINE;

ANTIANGIOGENIC ACTIVITY; CANCER CONTROL; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DNA IMMUNIZATION; DNA REPAIR; DRUG CARCINOGENICITY; EPIDERMODYSPLASIA VERRUCIFORMIS; EXCISION REPAIR; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE EVASION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KERATINOCYTE; METASTATIC MELANOMA; ORGAN TRANSPLANTATION; OROPHARYNX; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PRECANCER; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; SKIN PAPILLOMA; SKIN TRANSPLANTATION; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY; ULTRAVIOLET IRRADIATION; VERRUCA VULGARIS; VIRUS LOAD; VIRUS REPLICATION; WART VIRUS; XERODERMA PIGMENTOSUM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS; BASAL CELL CARCINOMA; BCC; CALCINEURIN INHIBITOR; CARCINOGENESIS; CNI; EGFR; EMT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMODYSPLASIA VERRUCIFORMIS; EPITHELIAL-MESENCHYMAL TRANSITION; EV; HIV; HPV; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; IFN; IMMUNOSUPPRESSION; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; MTOR; PAPILLOMAVIRUS; SCC; SCID; SEVERE COMBINED IMMUNODEFICIENCY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET LIGHT; UV; VACCINES; XERODERMA PIGMENTOSUM; XP;

ALPHAPAPILLOMAVIRUS; BETAPAPILLOMAVIRUS; CALCINEURIN; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; EPIDERMODYSPLASIA VERRUCIFORMIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MELANOMA; MUTATION; ONCOGENE PROTEINS, VIRAL; ORGAN TRANSPLANTATION; PAPILLOMAVIRUS INFECTIONS; RAF KINASES; RECEPTOR CROSS-TALK; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES; ULTRAVIOLET RAYS; VIRAL TROPISM; XERODERMA PIGMENTOSUM;

EID: 84888302558     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.08.005     Document Type: Review

References (99)

1. Rescigno M., Avogadri F., Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 2007, 1776:108-123.
2. Kalialis L.V., Drzewiecki K.T., Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009, 19:275-282.
3. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
4. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
5. Gogas H., Ioannovich J., Dafni U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718.
6. Trager U., Sierro S., Djordjevic G., et al. The immune response to melanoma is limited by thymic selection of self-antigens. PLoS One 2012, 7:e35005.
7. Cheever M.A., Higano C.S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011, 17:3520-3526.
8. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
9. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
10. Beaussant Cohen S., Fenneteau O., Plouvier E., et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis 2012, 7:71.
11. Lazarczyk M., Favre M. Role of Zn2+ ions in host-virus interactions. J. Virol. 2008, 82:11486-11494.
12. Crequer A., Picard C., Patin E., et al. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS One 2012, 7:e44010.
13. Ikehata H., Ono T. The mechanisms of UV mutagenesis. J Radiat Res 2011, 52:115-125.
14. Miyauchi-Hashimoto H., Sugihara A., Tanaka K., Horio T. Ultraviolet radiation-induced impairment of tumor rejection is enhanced in xeroderma pigmentosum a gene-deficient mice. J Invest Dermatol 2005, 124:1313-1317.
15. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
16. Royle J.A., Baade P.D., Joske D., Girschik J., Fritschi L. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 2011, 105:1076-1081.
17. Guarini A., Marinelli M., Tavolaro S., et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012, 97:47-55.
18. Flynn J.M., Andritsos L., Lucas D., Byrd J.C. Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus. Br J Haematol 2010, 149:388-390.
19. Wakita D., Chamoto K., Ohkuri T., et al. IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 2009, 30:1408-1415.
20. Engels E.A., Pfeiffer R.M., Fraumeni J.F., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306:1891-1901.
21. Johnson E.E., Leverson G.E., Pirsch J.D., Heise C.P. A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. J Gastrointest Surg 2007, 11:272-279.
22. Nindl I., Rosl F. Molecular concepts of virus infections causing skin cancer in organ transplant recipients. Am J Transplant 2008, 8:2199-2204.
23. Bangash H.K., Colegio O.R. Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients. Curr Treat Options Oncol 2012, 13:354-376.
24. Xu J., Walsh S.B., Verney Z.M., Kopelovich L., Elmets C.A., Athar M. Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway. Biochem Biophys Res Commun 2011, 408:363-368.
25. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
26. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005, 352:1317-1323.
27. Signorell J., Hunziker T., Martinelli M., Koestner S.C., Mohacsi P.J. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor-to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. Transpl Proc 2010, 42:3871-3875.
28. Wu X., Nguyen B.C., Dziunycz P., et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010, 465:368-372.
29. Ori Y., Herman-Edelstein M., Zingerman B., et al. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells. Biomed Pharmacother 2012, 66:409-413.
30. Patel S., Chiplunkar S. Host immune responses to cervical cancer. Curr Opin Obstet Gynecol 2009, 21:54-59.
31. Lewis J.S., Ukpo O.C., Ma X.J., et al. Transcriptionally-active high-risk human papillomavirus is rare in oral cavity and laryngeal/hypopharyngeal squamous cell carcinomas-a tissue microarray study utilizing E6/E7 mRNA in situ hybridization. Histopathology 2012, 60:982-991.
32. Metcalfe C., de Sauvage F.J. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011, 71:5057-5061.
33. Li T., Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009, 4:107-119.
34. Commandeur S., van Drongelen V., de Gruijl F.R., El Ghalbzouri A. Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma. Cancer Sci 2012, 103(12):2120-2126.
35. Xu Y., Shao Y., Zhou J., Voorhees J.J., Fisher G.J. Ultraviolet irradiation-induces epidermal growth factor receptor (EGFR) nuclear translocation in human keratinocytes. J Cell Biochem 2009, 107:873-880.
36. Kanitakis J., Baldassini S., Lora V., Euvrard S. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. Eur J Dermatol 2010, 20:167-171.
37. Gutierrez-Dalmau A., Revuelta I., Ferrer B., et al. Distinct immunohistochemical phenotype of nonmelanoma skin cancers between renal transplant and immunocompetent populations. Transplantation 2010, 90:986-992.
38. Pfefferle R., Marcuzzi G.P., Akgul B., et al. The human papillomavirus type 8 E2 protein induces skin tumors in transgenic mice. J Invest Dermatol 2008, 128:2310-2315.
39. Azzimonti B., Dell'oste V., Borgogna C., et al. The epithelial-mesenchymal transition induced by keratinocyte growth conditions is overcome by E6 and E7 from HPV16, but not HPV8 and HPV38: characterization of global transcription profiles. Virology 2009, 388:260-269.
40. Lazarczyk M., Cassonnet P., Pons C., Jacob Y., Favre M. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009, 73:348-370.
41. Le Poole C., Denman C.J., Arbiser J.L. Immunosuppression may be present within condyloma acuminata. J Am Acad Dermatol 2008, 59:967-974.
42. Hufbauer M., Lazic D., Reinartz M., Akgul B., Pfister H., Weissenborn S.J. Skin tumor formation in human papillomavirus 8 transgenic mice is associated with a deregulation of oncogenic miRNAs and their tumor suppressive targets. J Dermatol Sci 2011, 64:7-15.
43. Kohler A., Meyer T., Stockfleth E., Nindl I. High viral load of human wart-associated papillomaviruses (PV) but not beta-PV in cutaneous warts independent of immunosuppression. Br J Dermatol 2009, 161:528-535.
44. Shale M.J., Seow C.H., Coffin C.S., Kaplan G.G., Panaccione R., Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010, 31:20-34.
45. Paolini F., Carbone A., Benevolo M., et al. Human papillomaviruses, p16INK4a and Akt expression in basal cell carcinoma. J Exp Clin Cancer Res 2011, 30:108.
46. Schiller J.T., Buck C.B. Cutaneous squamous cell carcinoma: a smoking gun but still no suspects. J Invest Dermatol 2011, 131:1595-1596.
47. Iannacone M.R., Wang W., Stockwell H.G., et al. Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin. J Infect Dis 2012, 206:399-406.
48. Reuschenbach M., Tran T., Faulstich F., et al. High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. Br J Cancer 2011, 104:1334-1341.
49. Hufbauer M., Lazic D., Akgul B., Brandsma J.L., Pfister H., Weissenborn S.J. Enhanced human papillomavirus type 8 oncogene expression levels are crucial for skin tumorigenesis in transgenic mice. Virology 2010, 403:128-136.
50. Wallace N.A., Robinson K., Howie H.L., Galloway D.A. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog 2012, 8:e1002807.
51. Proby C.M., Harwood C.A., Neale R.E., et al. A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 2011, 11:1498-1508.
52. Weissenborn S., Neale R.E., Waterboer T., et al. Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients. Med Microbiol Immunol 2012, 201:117-125.
53. Campisi G., Panzarella V., Giuliani M., et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review). Int J Oncol 2007, 30:813-823.
54. Morrison M.A., Morreale R.J., Akunuru S., Kofron M., Zheng Y., Wells S.I. Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility. J Virol 2011, 85:10487-10498.
55. Lagunas-Martinez A., Madrid-Marina V., Gariglio P. Modulation of apoptosis by early human papillomavirus proteins in cervical cancer. Biochim Biophys Acta 2010, 1805:6-16.
56. Sokka M., Parkkinen S., Pospiech H., Syvaoja J.E. Function of TopBP1 in genome stability. Subcell Biochem 2010, 50:119-141.
57. Gillespie K.A., Mehta K.P., Laimins L.A., Moody C.A. Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. J Virol 2012, 86:9520-9526.
58. Kadaja M., Isok-Paas H., Laos T., Ustav E., Ustav M. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog 2009, 5:e1000397.
59. Zheng Z.M., Baker C.C. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006, 11:2286-2302.
60. Green K.L., Brown C., Roeder G.E., Southgate T.D., Gaston K. A cancer cell-specific inducer of apoptosis. Hum Gene Ther 2007, 18:547-561.
61. Beadle B.M., William W.N., McLemore M.S., Sturgis E.M., Williams M.D. p16 Expression in cutaneous squamous carcinomas with neck metastases: a potential pitfall in identifying unknown primaries of the head and neck. Head Neck 2012, 2012. doi: 10.1002/hed.23188.
62. Viarisio D., Mueller-Decker K., Kloz U., et al. E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog 2011, 7:e1002125.
63. Tan M.J., White E.A., Sowa M.E., Harper J.W., Aster J.C., Howley P.M. Cutaneous beta-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. Proc Natl Acad Sci USA 2012, 109:E1473-E1480.
64. Lefort K., Mandinova A., Ostano P., et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 2007, 21:562-577.
65. Brimer N., Lyons C., Wallberg A.E., Vande Pol S.B. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and Notch signaling. Oncogene 2012, 31:4639-4646.
66. Kang M.I., Baker A.R., Dextras C.R., Cabarcas S.M., Young M.R., Colburn N.H. Targeting of noncanonical Wnt5a signaling by AP-1 blocker dominant-negative Jun when it inhibits skin carcinogenesis. Genes Cancer 2012, 3:37-50.
67. Kannan S., Sutphin R.M., Hall M.G., et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med 2013, 210:321-337.
68. Narayan S., Choyce A., Linedale R., et al. Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+ CD25+ T cells. Eur J Immunol 2009, 39:481-490.
69. Panelos J., Massi D. Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther 2009, 8:1986-1993.
70. Venuti A., Paolini F., Nasir L., et al. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011, 10:140.
71. Hu L., Plafker K., Vorozhko V., et al. Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion. Virology 2009, 384:125-134.
72. Campo M.S., Graham S.V., Cortese M.S., et al. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 2010, 407:137-142.
73. Orth G. Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin Immunol 2006, 18:362-374.
74. Boulenouar S., Weyn C., Van Noppen M., et al. Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells. Carcinogenesis 2010, 31:473-480.
75. Ganguly N. Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value. Cell Oncol 2012, 35:67-76.
76. Nambaru L., Meenakumari B., Swaminathan R., Rajkumar T. Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac J Cancer Prev 2009, 10:355-360.
77. Hussain I., Fathallah I., Accardi R., et al. NF-kappaB protects human papillomavirus type 38 E6/E7-immortalized human keratinocytes against tumor necrosis factor alpha and UV-mediated apoptosis. J Virol 2011, 85:9013-9022.
78. Kim S.H., Oh J.M., No J.H., Bang Y.J., Juhnn Y.S., Song Y.S. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009, 30:753-757.
79. Vandermark E.R., Deluca K.A., Gardner C.R., et al. Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology 2012, 425:53-60.
80. Byg L.M., Vidlund J., Vasiljevic N., Clausen D., Forslund O., Norrild B. NF-kappaB signalling is attenuated by the E7 protein from cutaneous human papillomaviruses. Virus Res 2012, 169:48-53.
81. Alvarez J., de Pokomandy A., Rouleau D., et al. Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men. AIDS 2010, 24:2355-2363.
82. Moody C.A., Laimins L.A. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog 2009, 5:e1000605.
83. Oliveira S., Ribeiro J., Sousa H., Pinto D., Baldaque I., Medeiros R. Genetic polymorphisms and cervical cancer development: ATM G5557A and p53bp1 C1236G. Oncol Rep 2012, 27:1188-1192.
84. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
85. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
86. Friedland P., Thomas A., Naran A., et al. Human papillomavirus and gene mutations in head and neck squamous carcinomas. ANZ J Surg 2011, 82(5):362-366.
87. Rischin D., Young R.J., Fisher R., et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28:4142-4148.
88. Fallai C., Perrone F., Licitra L., et al. Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. Int J Radiat Oncol Biol Phys 2009, 75:1053-1059.
89. Kostareli E., Holzinger D., Hess J. New concepts for translational head and neck oncology: lessons from HPV-related oropharyngeal squamous cell carcinomas. Front Oncol 2012, 2:36.
90. Wansom D., Light E., Thomas D., et al. Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope 2012, 122:121-127.
91. Tseng C.W., Trimble C., Zeng Q., et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2009, 58:737-748.
92. Ulrich C., Jurgensen J.S., Degen A., et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24months, prospective, case-control study. Br J Dermatol 2009, 161(Suppl 3):78-84.
93. Raimondi A.R., Molinolo A., Gutkind J.S. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-Ras and p53 two-hit carcinogenesis model. Cancer Res 2009, 69:4159-4166.
94. Lobry C., Ntziachristos P., Ndiaye-Lobry D., et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 2013, 210:301-319.
95. Edwards T.G., Koeller K.J., Slomczynska U., et al. HPV episome levels are potently decreased by pyrrole-imidazole polyamides. Antiviral Res 2011, 91:177-186.
96. Gaston A., Garry R.F. Topical vitamin A treatment of recalcitrant common warts. Virol J 2012, 9:21.
97. Zwald F.O., Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management. Part II: Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011, 65:263-279. quiz 80.
98. Batman G., Oliver A.W., Zehbe I., Richard C., Hampson L., Hampson I.N. Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. Antivir Ther 2011, 16:515-525.
99. Amine A., Rivera S., Opolon P., et al. Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS One 2009, 4:e5018.